Pancreatic Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

Pancreatic Cancer has High Rate of Failures in Late Stage Clinical Trials

Online PR News – 20-May-2010 – – The pancreatic cancer market has fewer competitors than most cancer markets, despite being one of the most challenging forms of cancer to treat. The reason for this is the high incidence of failures in late stage clinical trials. In 2005, Supergen withdrew a filing for Orathecin as the data was insufficient to gain approval. Aphton also announced that its drug Insegia failed to meet its primary endpoint in the Phase III trial. GenVac announced the failure of TNFerade in 2010. Because of the immediate need for treatment, the FDA has deemed drugs and therapeutics for pancreatic cancer eligible for Fast Track Designations.

For further details, please click or add the below link to your browser:

Gemzar will remain the preferred drug of choice for the pancreatic cancer market, owing to its wide usage and strong physician acceptance. It also has a better side-effect profile than other chemotherapeutics. It is approved for a plethora of oncology indications: for the treatment of pancreatic, non-small cell lung cancer, metastatic breast, recurrent ovarian, and bladder cancer (only in the EU). GlobalData estimates that Gemzar accounts for about 60-65% of the pancreatic cancer market in the US and Europe. Eli Lilly is also in talks about developing an oral Gemzar prodrug with the potential for unique intellectual property protection, which, according to reports in 2010, was in Phase I. Gemzar’s patent expires in the US end 2010 but generic versions of Gemzar have already been launched in some Northern European countries This is expected to lead to an estimated depletion in market revenues between 2009 and 2013. The market is expected to stabilize by 2016.

For further details, please click or add the below link to your browser:

The unmet need in the pancreatic cancer market is high due to the limited options available for treatment. The lack of safe and highly efficacious products in the market has led to high unmet need which GlobalData expects to remain unchanged in the future since the pipeline does not have molecules that can significantly influence the unmet need. Pancreatic cancer has one of the highest mortality rates among cancers. The median survival time for metastatic pancreatic cancer is only three to six months. In such cases, highly efficacious drugs are difficult to develop and struggle to gain regulatory approvals since authorities have set up stringent protocols and expect a statistically significant improvement in overall survival before finally approving a new drug. This is done to avoid a serious adverse event that could possibly lead to the untimely death of a patient but it indirectly discourages newer drugs from entering the market. Thus the unmet need is expected to remain high.

GlobalData, the industry analysis specialist, has released its new report, “Pancreatic Cancer - Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global pancreatic cancer market. The report identifies the key trends shaping and driving the market, and provides insights on the prevalent competitive landscape and the emerging players expected to significantly shift the market positioning of the existing market leaders. Most importantly, the report provides a valuable insight on the pipeline products within the global pancreatic cancer market.

For further details, please click or add the below link to your browser:

Visit our report store: